3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Hepatocellular
6
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Nasopharyngeal Carcinoma
2
Squamous NSCLC
1
Squamous Cell Non-small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Non-small Cell Lung Cancer
1
Radiation Pneumonitis
1
Non-Squamous Non-Small Cell Lung Cancer
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
MSI-H
1
Lung Neoplasms
1
HER2+ Breast Cancer
1
Gastrointestinal Diseases
1
Esophageal Diseases
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Advanced Non-squamous Non-Small-Cell Lung Cancer
1
Interventions
sintilimab
1
nedaplatin
1
Pemetrexed
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Advanced Non-squamous Non-Small-Cell Lung Cancer
×
sintilimab
×
Clear all
NCT05648071
2022-12-13
SPBPDC
Qianfoshan Hospital
Phase 3
Unknown
60 enrolled